Zymeworks (ZYME) Stock Price & Analysis

ZYME$26.45+0.21 +0.80%
Biotechnology
Compare
Market cap$1.84BEnterprise value$2.17BRevenue (TTM)$265.97MMarket position—

Score

45
Neutral
Value
50
Quality
38
Growth
48

AI Analysis

Snapshot

Zymeworks scores 45/100, but the multiple is asking a lot (P/E 46.0). Under the hood: P/E 46.0, plus revenue compounding ~-14% annually over recent years. Street targets still imply ~64% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

50
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

48
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

38
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Zymeworks Inc. (ZYME) last printed $26.45. Equity value is $1.84B. Trailing earnings multiple 43.73. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$11.01M$51.76M$53.02M$29.54M$38.95M$26.68M$412.48M$76.01M$76.3M$105.97M

About

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Zymeworks (ZYME) Stock Price & Analysis

ZYME price $26.45 +0.21 +0.80%

Ticker
ZYME
Price
$26.45
Change
+0.21 +0.80%
Market cap
$1.84B
P/E
43.73
Forward P/E
55.70
Dividend yield
0.00%
Beta
1.17
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
45
Value
50
Quality
38
Growth
48

Stocklytics score rationale: value 50, quality 38, growth 48.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener